Sierra Radiopharmacy LLC

Sierra Radiopharmacy LLC, a for-profit limited liability company based in Reno, Nevada, manufactures and supplies radiopharmaceuticals and associated nuclear medicine diagnostic compounds to the Department of Veterans Affairs as a prime contractor in a full-and-open, non-set-aside posture. The vendor operates exclusively as a prime on federal work and holds no subcontractor relationships across its federal footprint.

Sierra Radiopharmacy serves a single customer agency — VA Veterans Integrated Service Network 21 (VISN 21) in northern Nevada — which accounts for all 23 active awards (99% of combined potential value, $7.5 million). The vendor supplies radiopharmaceuticals including Tc99m formulations, iodine-based products, indium compounds, and thallium and gallium isotopes to support nuclear medicine and diagnostic imaging at VA Sierra Nevada Health Care System in Reno. Regulatory requirements include Nuclear Regulatory Commission licensure, State Board of Pharmacy License, and State Department of Health and Human Service Health Division Bureau of Health Care Quality and Compliance certification. Representative awards include a $247,204 firm fixed-price purchase order issued August 5, 2026 with performance through August 31, 2027; a $252,379 delivery order from October 1, 2024 against the VA Reno Health Care System Radiopharmaceuticals indefinite delivery contract running through September 30, 2025; and earlier delivery orders valued at $206,116 (issued October 1, 2022) and $180,654 (issued January 1, 2022) against a $2.2 million IDIQ contract awarded January 1, 2022 with ultimate completion September 30, 2024.

Sierra Radiopharmacy places work under four single-award indefinite delivery vehicle contracts held with VISN 21, generating five task orders ($453 thousand combined potential value) under contract 36C26118D0081, three task orders ($631 thousand) under 36C26122D0050, two task orders ($562 thousand) under VA26117D0029, and one task order ($252 thousand) under 36C26125D0018. Combined obligated dollars across all awards total $4.1 million against $7.6 million in combined potential value (54% obligation rate). Activity has been intermittent — two awards in 2020, three in 2022, one in 2023, two in 2024, and one in 2026 — with only one award ($247 thousand) reaching ultimate completion within the next twenty-four months. The vendor's award portfolio concentrates under NAICS 325412 (Pharmaceutical Preparation Manufacturing) across 20 awards and PSC code for Drugs and Biologicals across 19 awards, reflecting its core radiopharmaceutical manufacturing and supply capability for VA diagnostic imaging operations.